US20260325440
2026-10-22
Human necessities
A61K9/0019
Immune cells engineered to express antigenic receptors, such as chimeric antigen receptors (CARs) and T cell receptors (TCRs), are described for treating immune-related disorders. These engineered cells can target specific antigens associated with tumors, offering a targeted approach to cancer therapy. The application addresses the limitations of current adoptive T cell therapies by enhancing specificity and dual targeting capabilities.
The engineered immune cells are capable of expressing human IL-15 and multiple antigen receptors, including CARs and TCRs. These cells can be autologous or allogeneic, derived from various cell types such as T cells, NK cells, and stem cells. The engineering process may involve additional cytokines and the suppression of specific receptors to enhance therapeutic efficacy while minimizing potential toxicity.
These immune cells can express antigen receptors with binding regions tailored to recognize tumor-associated antigens. This includes a variety of antigens like CD19, HER2/Neu, and EGFRvIII. The design allows for distinct antigen binding regions on different receptors, enabling the cells to target multiple antigens simultaneously, enhancing their tumor-fighting potential.
The engineered immune cells can be formulated into pharmaceutical compositions for treating immune-related disorders, including various cancers and inflammatory conditions. The compositions are designed to deliver effective doses of immune cells with specific antigen receptors to target and eradicate tumor cells while sparing healthy tissues.
Targeting specific cancers such as ovarian, lung, and breast cancer, these engineered immune cells provide a promising approach to treating both solid tumors and hematologic malignancies. By enhancing antigen specificity and reducing off-target effects, this technology aims to improve outcomes for patients with difficult-to-treat cancers and other immune-related disorders.